Global Psoriasis Drugs Market Size study, by Class, Treatment (Topicals, Systemic, Biologics), Route of Administration (Oral, Parenteral), Distribution Channel, and Regional Forecasts 2022-2032
Global Psoriasis Drugs Market is valued at approximately USD 19.2 billion in 2023 and is projected to surge with a compelling CAGR of more than 10.80% during the forecast period 2024–2032. Psoriasis, a chronic and often debilitating autoimmune skin disease, is witnessing a transformative shift in treatment paradigms with the advent of innovative pharmaceutical interventions. Traditionally managed with topical steroids and phototherapy, the market is now embracing advanced biologics and systemic therapies that target the disease at a molecular level. These treatments have proven to drastically enhance patient outcomes, offering longer remission periods and improved quality of life. As healthcare providers increasingly move toward patient-centric strategies, the demand for customized and efficacious treatment regimens has bolstered investment in novel drug development, pushing the psoriasis drugs market into an accelerated growth trajectory.
The momentum in this market is primarily fueled by the rising prevalence of psoriasis globally, coupled with a growing awareness of its comorbidities such as cardiovascular diseases, diabetes, and depression. Moreover, pharmaceutical firms are actively engaged in extensive clinical trials and research collaborations to expand their product pipelines, particularly in the biologics segment. The growing adoption of targeted immunomodulators and biosimilars is opening lucrative avenues for both existing players and new entrants. However, market progression is challenged by the high cost of biologics, complex regulatory frameworks, and uneven access to advanced therapeutics across developing economies. These barriers, though substantial, are being gradually mitigated by policy reforms, generic competition, and advancements in drug delivery systems.
Another catalyst for market expansion is the increasing use of precision medicine and genomics to guide therapy choices. Personalized drug protocols based on genetic and immune profiling are becoming more feasible, driving efficacy and reducing side effects. Additionally, patients are gravitating toward oral therapies and minimally invasive biologics, steering pharmaceutical companies to shift focus toward developing parenteral-free formats and enhancing treatment compliance. The integration of digital therapeutics and remote monitoring tools is also beginning to reshape how chronic dermatologic diseases are managed, setting a new standard in patient engagement and adherence monitoring.
From a geographical perspective, North America dominates the psoriasis drugs landscape, supported by strong reimbursement policies, high disease burden, and robust R&D activities. The U.S. in particular remains the innovation hub with rapid biologic approvals and widespread access to advanced care. Europe follows closely, with countries like Germany and the UK contributing significantly due to favorable healthcare infrastructure and high biologic penetration. Meanwhile, the Asia Pacific region is poised for exponential growth owing to increasing awareness, improving access to healthcare, and rising prevalence of psoriasis in countries such as India, China, and Japan. Latin America and the Middle East & Africa are anticipated to demonstrate gradual yet promising growth with the introduction of biosimilars and expansion of healthcare coverage.
Major market player included in this report are:
By Class
North America
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
The momentum in this market is primarily fueled by the rising prevalence of psoriasis globally, coupled with a growing awareness of its comorbidities such as cardiovascular diseases, diabetes, and depression. Moreover, pharmaceutical firms are actively engaged in extensive clinical trials and research collaborations to expand their product pipelines, particularly in the biologics segment. The growing adoption of targeted immunomodulators and biosimilars is opening lucrative avenues for both existing players and new entrants. However, market progression is challenged by the high cost of biologics, complex regulatory frameworks, and uneven access to advanced therapeutics across developing economies. These barriers, though substantial, are being gradually mitigated by policy reforms, generic competition, and advancements in drug delivery systems.
Another catalyst for market expansion is the increasing use of precision medicine and genomics to guide therapy choices. Personalized drug protocols based on genetic and immune profiling are becoming more feasible, driving efficacy and reducing side effects. Additionally, patients are gravitating toward oral therapies and minimally invasive biologics, steering pharmaceutical companies to shift focus toward developing parenteral-free formats and enhancing treatment compliance. The integration of digital therapeutics and remote monitoring tools is also beginning to reshape how chronic dermatologic diseases are managed, setting a new standard in patient engagement and adherence monitoring.
From a geographical perspective, North America dominates the psoriasis drugs landscape, supported by strong reimbursement policies, high disease burden, and robust R&D activities. The U.S. in particular remains the innovation hub with rapid biologic approvals and widespread access to advanced care. Europe follows closely, with countries like Germany and the UK contributing significantly due to favorable healthcare infrastructure and high biologic penetration. Meanwhile, the Asia Pacific region is poised for exponential growth owing to increasing awareness, improving access to healthcare, and rising prevalence of psoriasis in countries such as India, China, and Japan. Latin America and the Middle East & Africa are anticipated to demonstrate gradual yet promising growth with the introduction of biosimilars and expansion of healthcare coverage.
Major market player included in this report are:
- Johnson & Johnson Services, Inc.
- Novartis AG
- AbbVie Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- Bristol Myers Squibb
- Merck & Co., Inc.
- Sun Pharmaceutical Industries Ltd.
- UCB S.A.
- Takeda Pharmaceutical Company Limited
- Biocon Biologics Limited
- Boehringer Ingelheim International GmbH
- LEO Pharma A/S
- Galderma S.A.
By Class
- TNF Inhibitors
- Interleukin Inhibitors
- PDE4 Inhibitors
- Others
- Topicals
- Systemic
- Biologics
- Oral
- Parenteral
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
North America
- U.S.
- Canada
- UK
- Germany
- France
- Spain
- Italy
- ROE
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Brazil
- Mexico
- Saudi Arabia
- South Africa
- RoMEA
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
CHAPTER 1. GLOBAL PSORIASIS DRUGS MARKET EXECUTIVE SUMMARY
1.1. Global Psoriasis Drugs Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Class
1.3.2. By Treatment
1.3.3. By Route of Administration
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL PSORIASIS DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Raw Material Availability
2.3.3.2. Manufacturing Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Manufacturer Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Prescriber Awareness & Adoption
2.3.4.2. Patient Access & Affordability
2.3.4.3. Technological Advancements in Delivery
2.3.4.4. Social Acceptance & Stigma Reduction
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL PSORIASIS DRUGS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Prevalence of Psoriasis and Comorbidities
3.1.2. Surge in Biologics and Biosimilar Approvals
3.1.3. Advances in Precision Medicine and Genomic Profiling
3.2. Market Challenges
3.2.1. High Cost of Biologic Therapies
3.2.2. Complex Regulatory Pathways for Novel Agents
3.2.3. Uneven Access in Emerging Economies
3.3. Market Opportunities
3.3.1. Growth of Biosimilars and Generics
3.3.2. Expansion of Oral and At-Home Treatment Options
3.3.3. Strategic Collaborations between Pharma and Tech
CHAPTER 4. GLOBAL PSORIASIS DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY CLASS (2022–2032)
5.1. Segment Dashboard
5.2. TNF Inhibitors, Interleukin Inhibitors, PDE4 Inhibitors & Others: Revenue Trend Analysis, 2022 & 2032
CHAPTER 6. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY TREATMENT (2022–2032)
6.1. Segment Dashboard
6.2. Topicals, Systemic & Biologics: Revenue Trend Analysis, 2022 & 2032
CHAPTER 7. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)
7.1. Segment Dashboard
7.2. Oral vs. Parenteral: Revenue Trend Analysis, 2022 & 2032
CHAPTER 8. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)
8.1. Segment Dashboard
8.2. Hospital Pharmacies, Retail Pharmacies & Online Pharmacies: Revenue Trend Analysis, 2022 & 2032
CHAPTER 9. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY REGION (2022–2032)
9.1. North America Market
9.1.1. U.S. Market
9.1.1.1. Class Breakdown & Forecasts, 2022–2032
9.1.1.2. Treatment Breakdown & Forecasts, 2022–2032
9.1.2. Canada Market
9.2. Europe Market
9.2.1. U.K. Market
9.2.2. Germany Market
9.2.3. France Market
9.2.4. Spain Market
9.2.5. Italy Market
9.2.6. Rest of Europe Market
9.3. Asia Pacific Market
9.3.1. China Market
9.3.2. India Market
9.3.3. Japan Market
9.3.4. Australia Market
9.3.5. South Korea Market
9.3.6. Rest of APAC Market
9.4. Latin America Market
9.4.1. Brazil Market
9.4.2. Mexico Market
9.4.3. Rest of LATAM Market
9.5. Middle East & Africa Market
9.5.1. Saudi Arabia Market
9.5.2. South Africa Market
9.5.3. Rest of MEA Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Johnson & Johnson Services, Inc.
10.1.2. Novartis AG
10.1.3. AbbVie Inc.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Johnson & Johnson Services, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Novartis AG
10.3.3. AbbVie Inc.
10.3.4. Pfizer Inc.
10.3.5. Eli Lilly and Company
10.3.6. Amgen Inc.
10.3.7. Bristol Myers Squibb
10.3.8. Merck & Co., Inc.
10.3.9. Sun Pharmaceutical Industries Ltd.
10.3.10. UCB S.A.
10.3.11. Takeda Pharmaceutical Company Limited
10.3.12. Biocon Biologics Limited
10.3.13. Boehringer Ingelheim International GmbH
10.3.14. LEO Pharma A/S
10.3.15. Galderma S.A.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
1.1. Global Psoriasis Drugs Market Size & Forecast (2022–2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Class
1.3.2. By Treatment
1.3.3. By Route of Administration
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
CHAPTER 2. GLOBAL PSORIASIS DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Raw Material Availability
2.3.3.2. Manufacturing Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Manufacturer Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Prescriber Awareness & Adoption
2.3.4.2. Patient Access & Affordability
2.3.4.3. Technological Advancements in Delivery
2.3.4.4. Social Acceptance & Stigma Reduction
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
CHAPTER 3. GLOBAL PSORIASIS DRUGS MARKET DYNAMICS
3.1. Market Drivers
3.1.1. Rising Prevalence of Psoriasis and Comorbidities
3.1.2. Surge in Biologics and Biosimilar Approvals
3.1.3. Advances in Precision Medicine and Genomic Profiling
3.2. Market Challenges
3.2.1. High Cost of Biologic Therapies
3.2.2. Complex Regulatory Pathways for Novel Agents
3.2.3. Uneven Access in Emerging Economies
3.3. Market Opportunities
3.3.1. Growth of Biosimilars and Generics
3.3.2. Expansion of Oral and At-Home Treatment Options
3.3.3. Strategic Collaborations between Pharma and Tech
CHAPTER 4. GLOBAL PSORIASIS DRUGS MARKET INDUSTRY ANALYSIS
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Model
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
CHAPTER 5. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY CLASS (2022–2032)
5.1. Segment Dashboard
5.2. TNF Inhibitors, Interleukin Inhibitors, PDE4 Inhibitors & Others: Revenue Trend Analysis, 2022 & 2032
CHAPTER 6. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY TREATMENT (2022–2032)
6.1. Segment Dashboard
6.2. Topicals, Systemic & Biologics: Revenue Trend Analysis, 2022 & 2032
CHAPTER 7. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY ROUTE OF ADMINISTRATION (2022–2032)
7.1. Segment Dashboard
7.2. Oral vs. Parenteral: Revenue Trend Analysis, 2022 & 2032
CHAPTER 8. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY DISTRIBUTION CHANNEL (2022–2032)
8.1. Segment Dashboard
8.2. Hospital Pharmacies, Retail Pharmacies & Online Pharmacies: Revenue Trend Analysis, 2022 & 2032
CHAPTER 9. GLOBAL PSORIASIS DRUGS MARKET SIZE & FORECASTS BY REGION (2022–2032)
9.1. North America Market
9.1.1. U.S. Market
9.1.1.1. Class Breakdown & Forecasts, 2022–2032
9.1.1.2. Treatment Breakdown & Forecasts, 2022–2032
9.1.2. Canada Market
9.2. Europe Market
9.2.1. U.K. Market
9.2.2. Germany Market
9.2.3. France Market
9.2.4. Spain Market
9.2.5. Italy Market
9.2.6. Rest of Europe Market
9.3. Asia Pacific Market
9.3.1. China Market
9.3.2. India Market
9.3.3. Japan Market
9.3.4. Australia Market
9.3.5. South Korea Market
9.3.6. Rest of APAC Market
9.4. Latin America Market
9.4.1. Brazil Market
9.4.2. Mexico Market
9.4.3. Rest of LATAM Market
9.5. Middle East & Africa Market
9.5.1. Saudi Arabia Market
9.5.2. South Africa Market
9.5.3. Rest of MEA Market
CHAPTER 10. COMPETITIVE INTELLIGENCE
10.1. Key Company SWOT Analysis
10.1.1. Johnson & Johnson Services, Inc.
10.1.2. Novartis AG
10.1.3. AbbVie Inc.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Johnson & Johnson Services, Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Novartis AG
10.3.3. AbbVie Inc.
10.3.4. Pfizer Inc.
10.3.5. Eli Lilly and Company
10.3.6. Amgen Inc.
10.3.7. Bristol Myers Squibb
10.3.8. Merck & Co., Inc.
10.3.9. Sun Pharmaceutical Industries Ltd.
10.3.10. UCB S.A.
10.3.11. Takeda Pharmaceutical Company Limited
10.3.12. Biocon Biologics Limited
10.3.13. Boehringer Ingelheim International GmbH
10.3.14. LEO Pharma A/S
10.3.15. Galderma S.A.
CHAPTER 11. RESEARCH PROCESS
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
